These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25193599)

  • 1. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.
    Bedard G; Davies A; McDonald R; Hawley P; Buchanan A; Popovic M; Wong E; Chow E
    Support Care Cancer; 2015 Mar; 23(3):791-6. PubMed ID: 25193599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain.
    Bedard G; Hawley P; Zhang L; Slaven M; Gagnon P; Bisland S; Bennett M; Tardif F; Chow E
    Support Care Cancer; 2013 Sep; 21(9):2557-63. PubMed ID: 23636647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of breakthrough cancer pain].
    Sláma O
    Klin Onkol; 2013; 26(3):191-4. PubMed ID: 23763322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
    Zeppetella G
    Palliat Med; 2011 Jul; 25(5):516-24. PubMed ID: 21708858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
    Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
    Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
    Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
    Brząkała J; Leppert W
    Pharmacol Rep; 2019 Jun; 71(3):438-442. PubMed ID: 31003154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
    Romualdi P; Candeletti S
    Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.